Zacks Research Has Negative Forecast for AGIO Q1 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for Agios Pharmaceuticals in a research note issued to investors on Wednesday, December 11th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($1.64) for the quarter, down from their previous estimate of ($1.63). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($0.39) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.72) EPS, FY2025 earnings at ($6.77) EPS, Q1 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.41) EPS and FY2026 earnings at ($5.70) EPS.

A number of other research analysts have also issued reports on AGIO. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Scotiabank raised their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Finally, Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Stock Up 2.1 %

AGIO opened at $38.97 on Monday. The firm has a market cap of $2.22 billion, a P/E ratio of 3.43 and a beta of 0.80. The business’s fifty day simple moving average is $50.02 and its 200 day simple moving average is $46.76. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in Agios Pharmaceuticals during the second quarter valued at approximately $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the period. CWM LLC lifted its holdings in shares of Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Agios Pharmaceuticals during the 3rd quarter worth $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.